Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Selegiline hydrochloride - Generic Drug Details

« Back to Dashboard
Selegiline hydrochloride is the generic ingredient in three branded drugs marketed by Stason, Apotex, Somerset, G And W Labs Inc, Dava Pharms Inc, Lannett Holdings Inc, Vintage Pharms Llc, Mylan, Apotex Inc, Siegfried, and Valeant Pharm Intl, and is included in fifteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has twelve patent family members in twelve countries.

There are fifteen drug master file entries for selegiline hydrochloride. Ten suppliers are listed for this compound.

Summary for Generic Name: selegiline hydrochloride

Tradenames:3
Patents:1
Applicants:11
NDAs:15
Drug Master File Entries: see list15
Suppliers / Packaging: see list10
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: selegiline hydrochloride

Clinical Trials for: selegiline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dava Pharms Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074641-001Aug 2, 1996DISCNNo<disabled><disabled>
Lannett Holdings Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
CAPSULE;ORAL075145-001Sep 15, 2003DISCNNo<disabled><disabled>
Apotex
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
CAPSULE;ORAL075321-001Dec 4, 1998RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: selegiline hydrochloride

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 20065,648,093<disabled>
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 20066,423,342<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: selegiline hydrochloride

Country Document Number Estimated Expiration
Spain2160232<disabled in preview>
World Intellectual Property Organization (WIPO)9626714<disabled in preview>
Greece3036516<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc